103 completed, 26 recruiting, 17 terminated, 16 active not recruiting. 101 Phase 2, 74 Phase 1, 24 Phase 3, 2 Early Phase 1, 1 Phase 4.
Follow BeiGene: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2026-10-15 | 2026-10-21 |
| A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma Tislelizumab, FLOT Chemotherapy - Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 18 | 2025-12-12 | 2025-12-19 |
| Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia zanubrutinib + BGB-11417 - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 102 | 2025-12-01 | 2025-11-26 |
| A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC Tislelizumab + Anlotinib - SCLC, Limited Stage | Phase 2 | Recruiting | Yantai Yuhuangding Hospital | 20 | 2025-11-04 | 2026-09-11 |
| Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC Zanidatamab, Tislelizumab, Cisplatin - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Recruiting | Fujian Medical University Union Hospital | 25 | 2025-10-25 | 2025-12-22 |
| A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia Zanubrutinib - Waldenström's Macroglobulinemia | Phase 4 | Active not recruiting | BeiGene | 16 | 2025-10-17 | 2026-08-10 |
| Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei Pseudovax, Molgramostim, Tislelizumab - Pseudomyxoma Peritonei | Early Phase 1 | Recruiting | Oslo University Hospital | 10 | 2025-10-13 | 2026-01-14 |
| Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma Tislelizumab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer | Phase 2 | Recruiting | Ming-Yu Lien | 45 | 2025-09-26 | 2026-02-27 |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis BGB-45035, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | BeiGene | 49 | 2025-08-21 | 2026-05-28 |
| Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma Tislelizumab, Paclitaxel, Cisplatin - ESCC, Total Neoadjuvant Treatment | Phase 2 | Recruiting | National Taiwan University Hospital | 50 | 2025-07-23 | 2026-01-27 |
| Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer Tislelizumab & Fruquintinib - Metastatic Colorectal Cancer, mCRC | Phase 2 | Withdrawn | Sun Yat-sen University | 2025-07-01 | 2024-07-09 | |
| Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL Glofitamab, Polatuzumab Vedotin, Zanubrutinib - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 38 | 2025-06-20 | 2026-10-16 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma Zanubrutinib, Methotrexate, Polatuzumab Vedotin - CNS Lymphoma | Phase 1 | Recruiting | Juan P. Alderuccio, MD | 20 | 2025-04-17 | 2026-05-14 |
| tislelizUMaB in canceR Patients With molEcuLar residuaL Disease Tislelizumab, Blood sampling, Placebo - Cancer, Lung Cancer | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 717 | 2025-04-16 | 2025-05-13 |
| Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants BGB-16673, Itraconazole, Phenytoin - Healthy Volunteers | Phase 1 | Completed | BeiGene | 37 | 2025-04-03 | 2026-08-24 |
| Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma Obinutuzumab, Glofitamab, Venetoclax Oral Product - Lymphoma, Mantle-Cell | Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 100 | 2025-02-21 | 2026-07-10 |
| A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis HIPEC, SOX, Immune Checkpoint Inhibitors - Gastric Cancer | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 34 | 2025-02-15 | 2025-04-11 |
| A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants [14C]-BGB-16673 - Healthy Volunteers | Phase 1 | Completed | BeiGene | 8 | 2025-01-24 | 2025-05-01 |
Showing 20 of 186. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (16) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, Large B-Cell, Diffuse (9) · Recurrence (9) · Stomach Neoplasms (9) · Esophageal Squamous Cell Carcinoma (8) · Lymphoma, Mantle-Cell (8) · Waldenstrom Macroglobulinemia (8) · Carcinoma, Hepatocellular (7) · Colorectal Neoplasms (7) · Lymphoma, B-Cell, Marginal Zone (7) · Neoplasm Metastasis (7) · Lymphoma (6) · Neoplasms (6) · Lymphoma, Follicular (5)
tislelizumab (93) · zanubrutinib (46) · Cisplatin (19) · Paclitaxel (16) · Carboplatin (14) · pamiparib (13) · Pemetrexed (10) · Docetaxel (9) · sitravatinib (9) · Capecitabine (7) · Oxaliplatin (7) · Rituximab (7) · Fluorouracil (6) · Radiotherapy (6) · Chemoradiotherapy (5)
China (104) · United States (75) · Australia (46) · South Korea (32) · France (27) · Spain (26) · Taiwan (26) · Italy (20) · United Kingdom (20) · New Zealand (17) · Poland (15) · Germany (13) · Japan (9) · Russia (9) · Czechia (8)
William Novotny, MD (4) · William Novotony, MD (2) · Alison Freimund (1) · Arvind Dasari, MD (1) · Baohui Han, MD, PhD (1) · Brian Shuch, MD (1) · Caicun Zhou, PhD (1) · Christine Ryan, MD (1) · Cynthia Sirard, MD (1) · David Schiff, MD (1) · Dingwei Ye, MD (1)
PMID 38502198, PMID 38775302, PMID 35900694, PMID 36879284, PMID 40373876, PMID 32182156, PMID 34152395, PMID 34473343, PMID 42371751, PMID 22919026, PMID 26770954, PMID 28034070, PMID 28188133, PMID 28486951, PMID 28879531, PMID 28911074, PMID 29386072, PMID 29439186, PMID 29869556, PMID 30969136, PMID 31378459, PMID 31520078, PMID 31875923, PMID 32031037, PMID 32144955, PMID 32207333, PMID 32393328, PMID 32461234, PMID 32540858, PMID 32561664, PMID 33022066, PMID 33047430, PMID 33054121, PMID 33128299, PMID 33332484, PMID 33509647, PMID 33772633, PMID 33827139, PMID 33876576, PMID 34033975, PMID 34269067, PMID 34702811, PMID 34716199, PMID 34795408, PMID 35303070, PMID 35333492, PMID 35383885, PMID 35390135, PMID 35442766, PMID 35785595
2017 (9), 2018 (9), 2023 (7), 2016 (2), 2019 (2), U10CA180888 (1), UM1CA137443 (1)